Food or edible material: processes – compositions – and products – Dormant ferment containing product – or live microorganism...
Reexamination Certificate
1997-10-03
2002-04-02
Wong, Leslie (Department: 1761)
Food or edible material: processes, compositions, and products
Dormant ferment containing product, or live microorganism...
C426S063000, C426S285000, C426S573000, C435S188000
Reexamination Certificate
active
06365208
ABSTRACT:
The present invention relates to lactase tablets having improved chemical stability. More particularly, the present invention relates to lactase tablets containing lactase, microcrystalline cellulose, lubricant and mannitol.
BACKGROUND OF THE INVENTION
Lactose, or milk sugar, is a disaccharide carbohydrate which is hydrolyzed during the digestive process to glucose and galactose. This hydrolysis is catalyzed by the enzyme lactase, or beta-galactosidase. Although this enzyme is normally present in the intestinal juices and mucosa, investigations have shown that a significant portion of the population is lactose intolerant or lactase deficient. Consequently, there has been a great demand for a dietary supplement of lactose-hydrolyzing lactase enzymes in lactose intolerant individuals.
Commercially available tablets containing lactase have been observed to have an undesireably short shelf-life. Generally, it is desirable to have a shelf-life beyond about 24 months.
Shelf-life, as used herein for a lactase tablet product, is the time it takes for the lower 95% confidence interval of the product's potentcy plotted versus time to fall below a predetermined lower specification limit. Thus, it can be seen that shelf-life is a function of lactase content uniformity in the tablets and the inherent lactase chemical stability. It is an object of the present invention to formulate a lactase containing tablet composition having improved chemical stability.
SUMMARY OF THE INVENTION
Breifly, there is provided by the present invention a lactase tablet formulation comprising:
a) from about 1% to about 20% by weight of a combination of lactase and cutting agent where said combination has from 0 to about 4 parts by weight cutting agent for each part by weight lactase;
b) from about 1% to about 98% by weight of microcrystalline cellulose;
c) from about 0% to about 97% by weight of mannitol; and
d) an effective amount of lubricant to aid compression.
DETAILED DESCRIPTION OF THE INVENTION
Lactose hydrolyzing lactase enzymes are known to be produced by various yeasts, bacteria and fungi. Among the organisms heretofore disclosed as useful for this purpose are yeasts, such as,
Saccharomyces fragilis, Torula cremoris
and
Torula utilis
, bacteria, such as, Escherichia coli and
Lactobacillus bulgaricus
, fungi, such as,
Aspergillus oryzae, Aspergillus flavus
and
Aspergillus niger
, and various other micro-organisms, such as, those described in U.S. Pat. Nos. 2,681,858, 2,781,266 and 2,809,113. The lactase enzyme preparations produced by these organisms generally have pH optimums on the alkaline side or in the weakly acid pH range of about 5-7. Yeasts, which are the primary source of commercial lactases, are known to produce lactases having pH optimums of about 7. Most of these conventional lactase enzyme preparations contain other proteins in admixture therewith. When lactase is referred to herein, it is such an admixture that is referred to.
As seen, lactase enzymes are commercially produced as biological products which have a variability in potentcy from batch to batch that requires adjustment with a cutting agent in order to produce a uniform commercial product. Cutting agent is added to the lactase enzyme product and the amount is adjusted from batch to batch to produce a lactase enzyme product of the target potentcy. Cutting agents may be selected from any inert pharmaceutical excipient, including, sugars, starches, cellulose and inorganic salts. The amount or even the absence of the cutting agent herein is not critical to the present invention. Of course, it is desireable in the practice of the present invention that the lactase be in a readily available and convenient form of known potentcy for addition to the formulation. Suitable cutting agents include dextrose, mannitol, calcium phosphate, sodium citrate and microcrystalline cellulose.
Suitable lactase for use herein include, a lactase isolated from
Saccharomyces lactis
, by Gist-Brocade in Delft, Holland, and sold by Enzyme Development Corporation, New York, N.Y.; a lactase from
Aspergillus oryzae
, Lactase Y-400, produced by K. K. Yakult Honsha; a lactase from
Aspergillus oryzae
, Plexazym LA 1, produced by Roehm GmbH; a lactase from
Aspergillus oryzae
, produced by Shinnihon Kagaku Kogyo Co.; a lactase from
Kluyveromyces fragilis
produced by Sturges Enzymes, Selby, North Yorkshire, England; a lactase from
Aspergillus oryzae
, Takamine lactase, produced by Miles Laboratories, Inc., Elkhart, Ind.; and a lactase from
Kluyveromyces fragilis
produced by Novo Enzymes, Bagsvaerd, Denmark. These suppliers and others offer, generally, lactase, including a cutting agent, having a potentcy of between 14,000 and 100,000 FCC lactase units/gram. Preferrably the combination of lactase and cutting agent is present in the lactase tablet formulation in an amount of from about 5% to about 15% by weight and said combination has from about 0 to about 3 parts by weight cutting agent and more preferably from about 0.5 to about 2 parts by weight for each part by weight lactase. A preferred lactase for use herein is from
Aspergillus oryzae
produced by Amano Pharmaceutical Company, LTD, under the tradename Lactase F “Amano” 100. This preferred lactase contains, on a weight basis, about 50% a mixture containing sodium citrate and dextrose and the balance of lactase and has a potentcy of 100,000 FCC lactase units/gram.
Microcrystalline cellulose is manufactured by the controlled hydrolysis of alpha-cellulose, obtained as a pulp from fibrous plant materials, with dilute mineral acid solutions. Following hydrolysis, the hydrocellulose is purified by filtration and the aqueous slurry is spray dried to form dry, porous particles of a broad size distribution. Suitable microcrystalline cellulose will have an average particle size of from about 20 to about 200 &mgr;m. Microcrystalline cellulose is available from several suppliers. Suitable microcrystalline cellulose includes Avicel PH 101, Avicel PH 102, Avicel PH 103, Avicel PH 105 and Avicel PH 200, manufactured by FMC Corporation. Preferrably the microcrystalline cellulose is present in the lactase tablet formulation in an amount of from about 10% to about 85% by weight and more preferably in an amount of from about 25% to about 70% by weight.
Mannitol is a well known sweetner and excipient in pharmaceutical preparations. The mannitol should be ground to have an average particle size of between about 50 &mgr;m and about 500 &mgr;m prior to formulating. Preferrably the mannitol is present in the lactase tablet formulation in an amount of from about 15% to about 80% by weight and more preferably in an amount of from about 25% to about 70% by weight.
Examples of the lubricants include magnesium stearate, talc, polyethylene glycol, silica and hardened vegetable oils. The preferred lubricant is magnesium stearate. Preferrably, the lubricant is present in the lactase tablet formulation in an amount of from about 0.25% to about 6% and most preferably from about 0.5% to about 4% by weight.
In preparing the lactase tablets of this invention, the active lactase is simply mixed with the other ingredients and pressed into tablets by standard techniques. To achieve the benefit of the invention herein, it is not critical that any order of mixing be observed. However, it is the practice in formulating tablets, that the magnesium stearate is added as a last ingredient before compression. Also, it is preferred in making the tablets herein that the lactase is first thoroughly mixed with the microcrystalline cellulose before mixing with the mannitol.
The quantity of lactase enzyme administered in a single oral dosage can vary within wide limits. This quantity will depend on factors which include the lactase activity of the lactase enzyme, the magnitude of the lactase deficiency or lactose intolerance in the particular individual requiring the dietary supplement of lactase and the dietary habits of the individual. As a general matter, the affected individual will become accustomed to estimating a required dose based on
Kulkarni Sunanda R.
McFadden Robert T.
Rogers David H.
Walter, Jr. James T.
Mc-Neil-PPC, Inc.
Wong Leslie
LandOfFree
Stable lactase tablets does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable lactase tablets, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable lactase tablets will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2823959